(CNXT) ChiNext - Overview
Etf: Technology, Pharmaceuticals, Electronics, New-Energy
Dividends
| Dividend Yield | 0.18% |
| Yield on Cost 5y | 0.15% |
| Yield CAGR 5y | -63.54% |
| Payout Consistency | 35.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 32.8% |
| Relative Tail Risk | -12.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.61 |
| Alpha | 58.28 |
| Character TTM | |
|---|---|
| Beta | 0.570 |
| Beta Downside | 0.513 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.60% |
| CAGR/Max DD | 0.21 |
Description: CNXT ChiNext December 22, 2025
The VanEck ChiNext ETF (NYSE ARCA: CNXT) seeks to replicate its benchmark by allocating at least 80% of assets to the 100 largest and most liquid China A-shares listed on the ChiNext market of the Shenzhen Stock Exchange, using a free-float adjusted methodology.
Key data points to watch: the ChiNext index’s average price-to-earnings ratio has hovered around 22× in 2024, reflecting premium valuation for high-growth tech and biotech firms; quarterly net inflows into ChiNext-listed ETFs have risen ~15% YoY, indicating strong investor appetite; and Chinese policy support for innovation (e.g., the “Made in China 2025” upgrade) continues to drive sector weightings toward semiconductors, renewable energy, and digital services, which together account for roughly 55% of the index.
For a deeper, data-driven view of CNXT’s risk-adjusted performance, you might explore the analytics platform ValueRay.
What is the price of CNXT shares?
Over the past week, the price has changed by +1.71%, over one month by +0.50%, over three months by +8.79% and over the past year by +64.07%.
Is CNXT a buy, sell or hold?
What are the forecasts/targets for the CNXT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 52.8 | 13.5% |
CNXT Fundamental Data Overview February 10, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 66.1m USD (66.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 66.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 66.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.01% (E(66.1m)/V(66.1m) * Re(8.01%) + (debt-free company))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)